soul trial oral semaglutide cardiovascular outcomes 2024 results nejm 🚨 25 mg delivers double-digit weight loss in OASIS-4 (Phase 3 trial) - Oral Semaglutide's Impact on Cardiovascular

Name: soul trial oral semaglutide cardiovascular outcomes 2024 results nejm 🚨 25 mg delivers double-digit weight loss in OASIS-4 (Phase 3 trial) - Oral Semaglutide's Impact on Cardiovascular
Brand: matisco.be
SKU: 73682530330
Price: 25.85 USD
Availability: InStock
Rating: 4.5247 (10 reviews)

SKU: 73682530330

4.5

PLN25.85 PLN57.85

Pay in 4 interest-free payments of $6.46 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 1 - Aug 6

Live Spec

Oral Semaglutide's Impact on Cardiovascular Events in Type 2 Diabetes Patients with Cardiovascular and Kidney Disease: SOUL Trial Results PPTX Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular (CV) causes in patients with type 2 diabetes (T2D) and CKD ca. 2024 #ERA24 #Nephpearls https: www.nejm .org doi full 10.1056 NEJMoa2403347 NEJM Editorial Fellow Harleen Marwah, MD, summarizes the SOUL trial. Visit NEJM.org for the full trial results. #ACC25 #Cardiology #ClinicalTrials #MedTok #NEJM Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes New England Journal of Medicine

Store: matisco.be · Domain: matisco.be

Description

Rather than acting as classic enzyme inhibitors, artemisinins target Lon Peptidase 1(LONP1) in the mitochondria to facilitate the degradation of CYP11A1

These medications work best as part of a broader lifestyle approach, not as standalone solutions

Increasing the dose of a GLP-1 can sometimes enhance weight loss or maintain consistent weight loss, explained Fatima Cody Stanford, MD, an obesity medicine scientist at Massachusetts General Hospital Digestive Healthcare Center in Boston